NASDAQ:REGN Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $736.46 -6.37 (-0.86%) (As of 01/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$732.50▼$749.0050-Day Range$680.49▼$766.3952-Week Range$538.01▼$779.00Volume467,592 shsAverage Volume610,643 shsMarket Capitalization$80.20 billionP/E Ratio15.53Dividend YieldN/APrice Target$786.15 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Regeneron Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.65 Rating ScoreUpside/Downside8.4% Upside$798.65 Price TargetShort InterestHealthy1.38% of Float Sold ShortDividend StrengthN/ASustainability-1.68Upright™ Environmental ScoreNews Sentiment0.70Based on 30 Articles This WeekInsider TradingSelling Shares$14.07 M Sold Last QuarterProj. Earnings Growth-3.69%From $38.24 to $36.83 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.41 out of 5 starsMedical Sector247th out of 1,049 stocksPharmaceutical Preparations Industry119th out of 514 stocks 2.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 16 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $798.65, Regeneron Pharmaceuticals has a forecasted upside of 8.4% from its current price of $736.46.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.38% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently decreased by 6.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 64.79% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cancer medication (L01)", "Rheumatoid arthritis medication", and "Anakinra" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -1.68. Previous Next 2.6 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Regeneron Pharmaceuticals this week, compared to 9 articles on an average week.Search Interest19 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 171% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -53% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,071,258.00 in company stock.Percentage Held by InsidersOnly 8.99% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions84.25% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to decrease by -3.69% in the coming year, from $38.24 to $36.83 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 15.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.30.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 15.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 154.26.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.24. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 4.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Regeneron Pharmaceuticals (NASDAQ:REGN) StockRegeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.Read More Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Stock News HeadlinesJanuary 6, 2023 | marketbeat.comFour Undervalued Healthcare Stocks for 2023 (REGN)These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.January 31, 2023 | finance.yahoo.comRegeneron (REGN) Stock Moves -0.86%: What You Should KnowJanuary 31, 2023 | UNKNOWN (Ad)Invest in Brooklyn Gin: Hot craft spirits opportunityGet in on an award winning company in the fast growing craft spirits marketJanuary 30, 2023 | finance.yahoo.comEurope Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic EsophagitisJanuary 30, 2023 | finance.yahoo.comWill Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?January 30, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Outperform at CowenJanuary 30, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Raised to "Outperform" at CowenJanuary 30, 2023 | reuters.comSanofi and Regeneron's Dupixent wins new European Commission approvalJanuary 31, 2023 | UNKNOWN (Ad)Invest in Brooklyn Gin: Hot craft spirits opportunityGet in on an award winning company in the fast growing craft spirits marketJanuary 30, 2023 | msn.comSanofi, Regeneron Dupixent gets approval in EU for expanded use in eosinophilic esophagitisJanuary 30, 2023 | finance.yahoo.comDupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic EsophagitisJanuary 28, 2023 | americanbankingnews.comFY2022 EPS Estimates for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Cut by AnalystJanuary 27, 2023 | finance.yahoo.comWhy Regeneron (REGN) is Poised to Beat Earnings Estimates AgainJanuary 27, 2023 | markets.businessinsider.comRegeneron Pharma: CHMP Adopts Positive Opinion For DupixentJanuary 27, 2023 | finance.yahoo.comRegeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?January 27, 2023 | reuters.comSanofi's and Regeneron's Dupixent wins new stage of EU regulatory approvalJanuary 27, 2023 | finance.yahoo.comDupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic DermatitisJanuary 27, 2023 | finance.yahoo.comUPDATE 1-Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approvalJanuary 26, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $873.00 at Morgan StanleyJanuary 25, 2023 | marketwatch.comRegeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading dayJanuary 25, 2023 | finance.yahoo.com12 Cheap Biotech Stocks To BuyJanuary 24, 2023 | marketwatch.comRegeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms marketJanuary 24, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Regeneron (REGN) and Revance Therapeutics (RVNC)January 24, 2023 | finance.yahoo.comTop 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math CompetitionJanuary 23, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at JPMorgan Chase & Co.January 22, 2023 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $782.53 Consensus PT from AnalystsJanuary 22, 2023 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $782.53 Consensus PT from BrokeragesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Company Calendar Last Earnings11/03/2022Today1/30/2023Next Earnings (Confirmed)2/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees10,368Year Founded1988Price Target and Rating Average Stock Price Forecast$798.65 High Stock Price Forecast$970.00 Low Stock Price Forecast$625.00 Forecasted Upside/Downside+6.7%Consensus RatingModerate Buy Rating Score (0-4)2.65 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)$47.43 Trailing P/E Ratio15.53 Forward P/E Ratio19.26 P/E Growth2.24Net Income$8.08 billion Net Margins39.17% Pretax Margin44.04% Return on Equity31.16% Return on Assets23.61% Debt Debt-to-Equity Ratio0.13 Current Ratio5.36 Quick Ratio4.52 Sales & Book Value Annual Sales$16.07 billion Price / Sales4.99 Cash Flow$80.14 per share Price / Cash Flow9.19 Book Value$172.92 per share Price / Book4.26Miscellaneous Outstanding Shares108,900,000Free Float99,112,000Market Cap$80.20 billion OptionableOptionable Beta0.22 Social Links Key ExecutivesLeonard S. SchleiferCo-President, Chief Executive Officer & DirectorGeorge Damis YancopoulosCo-President, Director & Chief Scientific OfficerPatrice GiloolySenior VP-Quality Assurance & OperationsRobert E. LandryChief Financial Officer & Executive VP-FinanceNeil StahlExecutive VP-Research & DevelopmentKey CompetitorsVertex PharmaceuticalsNASDAQ:VRTXAlnylam PharmaceuticalsNASDAQ:ALNYBioMarin PharmaceuticalNASDAQ:BMRNZoetisNYSE:ZTSGSKNYSE:GSKView All CompetitorsInsiders & InstitutionsNew York State Common Retirement FundBought 46 shares on 1/30/2023Ownership: 0.170%Signaturefd LLCBought 93 shares on 1/30/2023Ownership: 0.002%Howland Capital Management LLCSold 40 shares on 1/30/2023Ownership: 0.001%James Investment Research Inc.Bought 80 shares on 1/30/2023Ownership: 0.000%Riggs Asset Managment Co. Inc.Sold 50 shares on 1/30/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions REGN Stock - Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGN shares. View REGN analyst ratings or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price forecast for 2023? 20 brokerages have issued 1 year price objectives for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $625.00 to $970.00. On average, they predict the company's share price to reach $798.65 in the next year. This suggests a possible upside of 8.4% from the stock's current price. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts. How have REGN shares performed in 2023? Regeneron Pharmaceuticals' stock was trading at $721.49 on January 1st, 2023. Since then, REGN shares have increased by 2.1% and is now trading at $736.46. View the best growth stocks for 2023 here. When is Regeneron Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 3rd 2023. View our REGN earnings forecast. How can I listen to Regeneron Pharmaceuticals' earnings call? Regeneron Pharmaceuticals will be holding an earnings conference call on Friday, February 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings data on Thursday, November, 3rd. The biopharmaceutical company reported $9.98 earnings per share for the quarter, beating analysts' consensus estimates of $8.55 by $1.43. The biopharmaceutical company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.79 billion. Regeneron Pharmaceuticals had a net margin of 39.17% and a trailing twelve-month return on equity of 31.16%. What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). What is Regeneron Pharmaceuticals' stock symbol? Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN." Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Sustainable Growth Advisers LP (0.40%), Sumitomo Mitsui Trust Holdings Inc. (0.35%), New York State Common Retirement Fund (0.17%), New York State Teachers Retirement System (0.11%), Assenagon Asset Management S.A. (0.11%) and Pendal Group Ltd (0.11%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Regeneron Pharmaceuticals' stock price today? One share of REGN stock can currently be purchased for approximately $736.46. How much money does Regeneron Pharmaceuticals make? Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $80.20 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $47.43 on an earnings per share basis. How many employees does Regeneron Pharmaceuticals have? The company employs 10,368 workers across the globe. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More How can I contact Regeneron Pharmaceuticals? Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113. This page (NASDAQ:REGN) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.